Clinical trials: Poliovirus Vaccine, Inactivated
Diphtheria, Tetanus
Database Surveillance Safety Study of PENTACEL® Vaccine
The objective for this study is to characterize the safety profile of PENTACEL® vaccine for identification of potential vaccine-related adverse events not currently associated with PENTACEL® vaccine administration.
- Conditions
- Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae
- Trial name
- NCT00804284
- Testing
- DTaP-IPV/Hib, Other DTap Vaccines
- Where
- United States
- Volunteers
- 62,538 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
This study is a Phase IV, open, randomized, multi-center, controlled vaccine trial conducted in healthy Latin American infants, utilizing one or two supplemental doses of IPV in children previously vaccinated with 3 doses of…
- Trial name
- NCT01831050
- Testing
- Bivalent Oral Polio Vaccine (bOPV), Trivalent Oral Polio Vaccine (tOPV), Monovalent Oral Polio Vaccine Type 2 (mOPV2)
- Where
- 4 sites in Colombia, Dominican Republic and 2 more
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Poliomyelitis
Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China
This study aims to obtain the direct domestic IPV vaccine monitoring data for the CNBG products, and provide scientific evidence for the National Immunization Program and long-term polio vaccine immunization policy.
- Trial name
- NCT03546634
- Testing
- Sabin IPV
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Healthy
Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV
This study is to assess protectivity following four doses of bOPV which given simultaneously with Pentabio® and 1 dose of IPV at the 4th visit
- Trial name
- NCT03310073
- Testing
- bOPV, Pentabio, IPV
- Where
- Indonesia
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Poliomyelitis
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months
The trial is a phase III, non-inferiority, observer-blind, randomised, controlled, multicentre clinical trial with 2 parallel groups: IPV-Al SSI (investigational vaccine) and IPV SSI (reference vaccine)
- Trial name
- VIPV-06 (NCT03032419)
- Testing
- IPV-Al SSI, IPV SSI
- Where
- Philippines
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Poliomyelitis
The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains
The purpose of this study is to evaluate the safety and the immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains by different does.
- Trial name
- IPV (NCT01048190)
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strains)
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Healthy
A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults
The main purpose of this study is to assess the safety and tolerability of a single dose of JNJ-64152348, inactivated poliovirus vaccine produced from Sabin poliovirus strains on PER.C6 cells (sIPV) in healthy adults, using…
- Trial name
- NCT03032588
- Testing
- sIPV, cIPV
- Where
- Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Polio
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV
The goal of this clinical trial is to explore two strategies to enhance nOPV2 immunogenicity in the field and overcome potential interference of bOPV: 1.
- Trial name
- NCT06114810
- Testing
- polio vaccines: nOPV2, bOPV, IPV
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Active Immunization
Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine
The trial is a parallel group, multi-centre, randomized, double blind, non-inferiority trial investigating the immunogenicity and safety of two DTaP-IPV combination vaccines: A)The investigational vaccine: DTaP-IPV containing IPV…
- Trial name
- NCT00655148
- Testing
- DTaP-IPV vero vaccine, DTaP-IPV mkc vaccine
- Where
- 5 sites in Poland
- Volunteers
- 817 people
- Sponsor
- Statens Serum Institut
Poliomyelitis
Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly
The purpose of this study is to investigate the use of a fourth fractional booster dose of sanofi pasteur's IMOVAX Polio injected intradermally (using the Mantoux technique) as booster dose between 15 to 18 months of age, in…
- Trial name
- NCT00885157
- Testing
- Inactivated types 1, 2, and 3 poliovirus, D antigens
- Where
- Philippines
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '1+2' sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822754
- Testing
- sIPV-bOPV-bOPV vaccination schedule, wIPV-bOPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Diphtheria, Tetanus
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
The study will assess the safety of Pentaxim® vaccine as a three-dose primary vaccination at 2, 3, and 4 months of age in order to meet the regulatory requirements for the license renewal as for any other product registered in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT01491087
- Testing
- DTacP IPV//PRP~T combined vaccine: PENTAXIM®
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Polio, Poliomyelitis
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
The purpose of this study is to generate data to support the registration extension of IMOVAX Polio to be used in a sequential vaccination.
- Trial name
- NCT01475539
- Testing
- Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio, Live oral poliovirus type 1, 2 and 3
- Where
- China
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a "2+1"Sequential Schedule With bOPV in Infants
The purpose of this phrase III clinical trial is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in a '2+1'sequential schedule with bivalent oral poliovirus vaccine in 2-month-old…
- Trial name
- NCT03822767
- Testing
- sIPV-sIPV-bOPV vaccination schedule, wIPV-wIPV-bOPV vaccination schedule
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Poliomyelitis
Safety of Imovax Polio in Chinese Infants and Children
To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of IMOVAX Polio™ administered in children and infants.
- Trial name
- NCT00258843
- Testing
- Inactivated Poliomyelitis vaccine
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.
- Trial name
- NCT00937404
- Testing
- Poliorix
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Polio
Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan
The aim of the study is to assess the immunogenicity of SP059 (IMOVAX POLIO®: Inactive Poliovirus Vaccine) vaccine against poliovirus and safety after fifth dose.
- Trial name
- NCT02005536
- Testing
- IMOVAX POLIO®: Inactive Poliovirus Vaccine
- Where
- 4 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Safety and Immunogenicity of IPOVAC in Young Children
A dose escalating study with 3 different dosing regimens of the studied vaccine (IPOVAC- POLYVAC-Vietnam) and a licensed vaccine (IMOVAC-Sanofi Pasteur- France) is conducted in Vietnamese children, aged 2 months and above to…
- Trial name
- NCT02775942
- Testing
- IMOVAC-POLIO, IPOVAC 1.5:5:5, IPOVAC, 3:10:10
- Where
- 2 sites in Vietnam
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Poliomyelitis
Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules
This is a phase IV open-label randomized clinical trial that will compare intestinal and humoral immunity in infants receiving inactivated poliovirus vaccine (IPV) and two or three doses of bivalent oral poliovirus vaccine (bOPV).
- Trial name
- NCT02412514
- Testing
- bOPV (three dose), bOPV (two dose), IPV
- Where
- Bangladesh
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
This first-in-human (FIH) phase 1 study is designed to evaluate in contained conditions the safety, immunogenicity, shedding, and genetic stability of two novel oral polio vaccine type 2 (nOPV2) vaccine candidates in IPV-primed…
- Trial name
- nOPV2M4a (NCT03430349)
- Testing
- Novel OPV2 candidate 1, Novel OPV2 candidate 2
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pierre Van Damme